Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label everolimus roll-over study in patients benefiting from prior Novartis everolimus trials
2012-004707-12Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of everolimus in cancer (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety: frequency and severity of adverse events and serious adverse events. Started Mar 2013; status: completed.
02
Drugs
everolimus
03
Conditions
cancer
Beyond the preview
Go deeper on 2012-004707-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004707-12.